Herazo-Maya JD, et al. - This study entailed the validation of a 52-gene risk profile for outcome prediction in patients with idiopathic pulmonary fibrosis (IPF). Findings demonstrated that in this patient population, the peripheral blood 52-gene expression signature served as a predictor of outcome. A recommendation was made for conducting prospective studies to determine the potential value of the 52-gene signature in predicting response to therapy.